Last reviewed · How we verify
MT-1303
At a glance
| Generic name | MT-1303 |
|---|---|
| Also known as | Amiselimod |
| Sponsor | Bausch Health Americas, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis (PHASE2)
- Extension Study of MT-1303 in Subjects With Crohn's Disease (PHASE2)
- Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients (PHASE1)
- Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease (PHASE2)
- Dose-finding Study of MT-1303 (PHASE2)
- Extension Study of MT-1303 (PHASE2)
- Comparative Oral Bioavailability Study of MT-1303 (PHASE1)
- Mass Balance Study of MT-1303 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MT-1303 CI brief — competitive landscape report
- MT-1303 updates RSS · CI watch RSS
- Bausch Health Americas, Inc. portfolio CI